DCTH:NASDAQ
Delcath Systems Inc
၁၂.၂၆ US$
arrow_upward
+၆.၅၂%(+၀.၇၅) 1D
ဇွန် ၂၃, GMT-၄ ၁၃:၁၄:၃၄ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DCTH...
Open
၁၁.၃၈ US$
High
၁၂.၃၈ US$
Low
၁၁.၃၅ US$
Mkt. cap
၄၂.၃၂ ကုဋေ
Avg. vol.
၅.၄၉ သိန်း
Volume
၃.၄၅ သိန်း
P/E ratio
၂,၀၄၆.၇၄
52-wk high
၁၄.၁၈ US$
52-wk low
၈.၁၂ US$
EPS
၀.၀၁ US$
Beta
၀.၅၄
Shares outstanding
၃.၄၅ ကုဋေ
No. of employees
၁၅၆
Open
၁၁.၃၈ US$
High
၁၂.၃၈ US$
Low
၁၁.၃၅ US$
Mkt. cap
၄၂.၃၂ ကုဋေ
Avg. vol.
၅.၄၉ သိန်း
Volume
၃.၄၅ သိန်း
P/E ratio
၂,၀၄၆.၇၄
52-wk high
၁၄.၁၈ US$
52-wk low
၈.၁၂ US$
EPS
၀.၀၁ US$
Beta
၀.၅၄
Shares outstanding
၃.၄၅ ကုဋေ
No. of employees
၁၅၆
News stories
From sources across the web
Caledonian Record
·
ပြီးခဲ့သည့် ၄၂ မိနစ်
ELWT Investor News: If You Have Suffered Losses in Elauwit Connection, Inc. (NASDAQ: ELWT), You ...
Yahoo Finance
·
ပြီးခဲ့သည့် ၁၈ မိနစ်
A Look Back at Processors and Graphics Chips Stocks’ Q1 Earnings: Broadcom (NASDAQ:AVGO) Vs The Rest Of The Pack
The Motley Fool
·
ပြီးခဲ့သည့် ၁၁ မိနစ်
Interest Rates Are Likely to Rise This Year. Here's What That Could Mean for the S&P 500
CBS News
·
ပြီးခဲ့သည့် ၃ နာရီ
Tech stocks tumble for a second day. Here's what is behind the selloff.
Profile
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
About Delcath Systems Inc
CEOGerard Michel
Employees၁၅၆
Founded၁၉၈၈
HeadquartersQueensbury, နယူးယောက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitedelcath.com
AI content may include mistakes. Learn more